扶正抗瘤方辅助伊立替康及顺铂治疗局限期小细胞肺癌疗效及对患者生活质量的影响

目的探讨扶正抗瘤方辅助伊立替康及顺铂治疗局限期小细胞肺癌(Limited stage small cell lung cancer,LD-SCLC)疗效及对患者生活质量的影响。方法将2014年3月—2016年3月期间收治的180例LD-SCLC患者为研究对象,按随机数字表法分为治疗组(90例)和对照组(90例)。对照组采用伊立替康+顺铂(IP)化疗方案治疗,治疗组在此基础上加用扶正抗瘤方进行治疗,化疗3周为1个疗程,连续治疗2个化疗周期后对两组患者疗效、免疫功能、血清肿瘤标志物水平以及生活质量进行比较。结果治疗组患者总有效率为83.33%,对照组为65.56%,两组差异有统计学意义(P<0.05);免疫功能:经治疗,两组CD3+、CD4+、CD4+/CD8+比值均有明显上升,CD8+水平明显下降(P<0.05);与对照组相比,治疗组CD3+、CD4+与CD4+/CD8+比值明显升高,CD8+水平明显降低,差异有统计学意义(P<0.05);血清肿瘤标记物:经治疗,两组患者血清中癌胚抗原(carcino-embryonic antigen,CEA)与神经元特异性烯醇化酶(neuron-specific enolase,NSE)浓度均显著降低,与对照组相比,治疗组明显低于对照组(P<0.05);生活质量:经治疗,治疗组患者在躯体、角色、社会、情绪、认知功能5方面评分均明显优于对照组(P<0.05)。结论扶正抗瘤方与IP治疗方案联合应用可以明显提高LD-SCLC患者的机体免疫力,降低血清肿瘤标记物的水平,改善患者的生活质量,因此对LD-SCLC具有积极的治疗效果。

Influence of Fuzheng Kangliu Recipe,Irinotecan and Cisplatin on Quality of Life with Limited Stage Small Cell Lung Cancer and Its Clinical Efficacy

Objective To study the influence of Fuzheng Kangliu Recipe,irinotecan and cisplatin on quality of life with limited stage small cell lung cancer(LD-SCLC)and its clinical efficacy.Methods From March 2014 to March 2016,180 patients with LD-SCLC were divided into treatment group and control group,90 cases in each group.The control group was treated with irinotecan and cisplatin(IP)chemotherapy.The treatment group was treated with Fuzheng Kangliu Recipe on the basis of chemotherapy.The chemotherapy was given for 3 weeks.The efficacy,immune function,serum level of tumor markers and quality of life of the two groups were compared after two cycles of chemotherapy.Results The total effective rate was 83.33%in treatment group and was 65.56%in control group,indicating significant difference(P<0.05).The level of CD3+,CD4+and CD4+/CD8+were significantly increased than those of the two groups,while the level of CD8+was significantly decreased than that of the two groups.Compared with the control group,the level of CD3+,CD4+and CD4+/CD8+was increased and CD8+decreased in treatment group,indicating significant difference(P<0.05).The serum levels of carcino embryonic antigen(CEA)and neuron-specific enolase(NSE)in the two groups were significantly lower than those in the control group(P<0.05).After treatment,the scores of body,role,society,emotion and cognitive function in the treatment group were significantly better than those in the control group(P<0.05).ConclusionThe combination of Fuzheng Kangliu Recipe,irinotecan and cisplatin chemotherapy can significantly improve the body immunity,reduce the level of serum tumor markers,and improve the quality of life with LD-SCLC patients,so it has a positive therapeutic effect on LD-SCLC.